BioNTech (BNTX) CEO Sahin Ugur Sells 20,500 Shares

What Happened

• Sahin Ugur, CEO of BioNTech SE, disposed of 20,500 ordinary shares on Sept. 10, 2026 in an open-market sale at $96.31 per share, for a total proceeds of $1,974,287. This was a sale (not a purchase) and was executed under a pre-established Rule 10b5-1 trading plan, which is commonly used to automate insider sales.

Key Details

• Transaction date and price: Sept. 10, 2026 — 20,500 shares sold at $96.31 each.
• Total proceeds: $1,974,287 (approximately $1.97M).
• Shares owned after transaction: Not specified in this Form 4; beneficial ownership is reported through Medine GmbH (see footnote).
• Footnote: The shares are held by Medine GmbH, of which Sahin Ugur is the sole shareholder. 106,721 shares reported are held for the benefit of an individual under a trust where Medine exercises voting but not dispositive power. The reporting person may be deemed to beneficially own the shares held by Medine GmbH.
• Trading plan: The sales were effected pursuant to a Rule 10b5-1 plan established by the reporting person on June 3, 2026.
• Filing timeliness: Form filed Sept. 11, 2026 for a Sept. 10 transaction — the filing does not indicate a late report.

Context

• Sales under a 10b5-1 plan are pre-scheduled and often viewed as routine liquidity actions rather than real-time statements about company prospects. There were no option exercises, gifts, or awards reported in this filing.